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Abstract
This article illustrates some issues we faced during our experience in conducting
an epidemiologic case–control study of inflammatory breast cancer in North
Africa. We expect that some of the questions we had to ask in order to address
these issues might be helpful to others in setting up epidemiologic studies in
developing regions. We describe our experience from different angles including
the use of multiple sites to achieve adequate sample size, standardizing diag-
nosis of disease, identifying cancer cases at the time of diagnosis, control selec-
tion procedures, logistics of study implementation, questionnaire development
and interviewing, biologic specimens, and procedures for protection of human
subjects. We have developed a brief checklist to summarize important issues for
conducting future epidemiologic studies in these or similar low- or middle-
income countries.
Introduction
Designing and conducting epidemiologic studies in devel-
oping countries can be very challenging due to lack of
research and medical infrastructures at study centers,
including personnel trained in epidemiology. In this man-
uscript, we share our experience in designing and con-
ducting an ongoing epidemiologic case–control study of
inflammatory breast cancer (IBC) in North Africa that
included a molecular epidemiology component.
For background, IBC is a rare, aggressive form of breast
cancer characterized by the rapid clinical appearance of
erythema (redness), edema, and peau d’orange of the
breast. Several studies have reported that IBC constitutes
a larger proportion of breast cancers in North Africa than
in the United States [1, 2], although the proportion of
IBC in some parts of Tunisia appears to be declining [3].
This is why we chose to do the case–control study in
Egypt, Tunisia, and Morocco. Our study includes IBC
cases, a sample of non-IBC cases, and visitor controls. We
collected information via questionnaires, medical record
review, clinical examination, anthropometric measure-
ments, saliva samples, tumor tissue, and digital photo-
graphs of the breast for the cases and questionnaire,
anthropometric measurements, and saliva for the
controls.
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Our aim in this study is not to describe the specifics of
the ongoing study on IBC, but rather to focus on issues
that we faced in mounting this low-budget, low-
technology study that might be pertinent to other epi-
demiologic studies in developing regions. These issues
include (1) enrolling study subjects at multiple study sites
to achieve adequate sample size; (2) standardizing the
diagnosis of a disease that has a clinical component; (3)
identifying study subjects with a specific disease before
treatment is initiated from among many patients seen at
study hospitals; (4) sampling cancers as a comparison
group; (5) control selection procedures when cases may
not be population-based and when hospital-based con-
trols are not feasible; (6) logistics of study implementa-
tion in a low-technology setting; (7) development of
questionnaires that are relevant to the study population;
(8) collection of biologic specimens, including fixation
procedures; (9) data management issues; and (10) issues
regarding protection of human subjects. We also provide
guidelines for determining whether other settings are
feasible for conducting epidemiologic studies.
Methods
Selection of study sites to accrue a
sufficient sample size
Because IBC is rare, we needed to include a number of
study hospitals and accrue patients over a relatively long
period of time. This posed challenges with regard to stan-
dardization of study procedures over both space and
time. We selected study sites for the case–control study
based on existing relationships with investigators at vari-
ous study sites, infrastructure for patient recruitment and
conducting clinical and epidemiologic studies [4–9],
interest among study clinicians in collaborating, availabil-
ity of a relatively large number of cases to obtain reason-
able sample size, and variety of patient backgrounds. To
achieve maximum sample size, we selected large referral
cancer centers, such as the National Cancer Institute
(NCI) – Cairo in Egypt, the Salah Azaiz Cancer Institute
in Tunisia, and the Ibn Rochd Oncology Center in Mor-
occo. NCI-Cairo’s patient population comes from all
parts of Egypt with approximately 45% of patients from
Cairo metropolitan area, 30% from the Delta region, and
25% from South Egypt [10]. The Salah Azaiz Cancer
Institute’s patient population comes mainly from the
Tunis metropolitan area and North Tunisia, but patients
from central and southern parts of Tunisia also come for
diagnosis and treatment [11, 12]. The Ibn Rochd Oncolgy
Center is a referral center for patients from the Southern
half of Morocco and is home of the population-based
cancer registry of Morocco [13]. In all, we included three
cancer centers in Egypt, one cancer center in Tunisia, one
cancer center in Morocco, and one university hospital in
Morocco.
Increasing number of participating hospitals in each
country required adjustment of the study procedures to
suit each hospital situation without compromising the
integrity of the study. For instance, case and control iden-
tification procedures had to be modified for each study
hospital (to be described later). Ideally, it is logistically
easiest to recruit study subjects from as few study hospi-
tals as possible to achieve sufficient sample size.
Investigators who intend to initiate a new study in mid-
dle- and low-income countries without prior contacts at
study hospitals can research existing literature to identify
centers with research experience. Some major cancer
centers provide information on websites (e.g., www.nci.
edu.e.g for the NCI-Cairo). Furthermore, new investiga-
tors can network with investigators who were funded to
conduct studies in developing countries by searching data-
bases such as the Reporter website of National Institute of
Health (NIH) (http://projectreporter.nih.gov/reporter.cfm)
or ongoing studies or publications of the International
Agency for Research on Cancer (http://www.iarc.fr/).
Methods to standardize the diagnosis of
IBC, a disease whose diagnosis has a clinical
component
IBC is largely a clinical diagnosis, although confirmation
of cancer by pathologic evidence is also required. Stan-
dardization of clinical diagnoses, which are inherently
somewhat subjective, across study hospitals and countries
can be challenging. The procedures we describe below for
IBC may be helpful in the standardization of diagnoses of
other diseases with a clinical component. With regard to
IBC, we wanted to capture and standardize the degree of
redness, edema, and peau d’orange of the breast leading
to a diagnosis of IBC. We also wanted to distinguish
between IBC and other forms of locally advanced breast
cancer. To standardize the clinical diagnosis, we first con-
ducted a pilot study in which cases determined to be IBC
at two of the study hospitals were enrolled over a 7- to
9-month period and asked to consent to digital photo-
graphs of the breast and detailed clinical examinations in
which the presence, extent, and duration of various signs/
symptoms of IBC were recorded. We then established sev-
eral layers of review, first at the study hospitals by senior
clinicians and then by two oncologists in the United
States, who reviewed the photographs and clinical infor-
mation. We used the results of the pilot study to establish
specific guidelines for the case–control study and to train
collaborators on the inclusion criteria for the case–control
study. We continued the collection of digital photographs
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of the breast and detailed clinical information during the
case–control study. Digital photographs are uploaded to
the study portal (which is an online document publishing
system and collaborative software tool that is password
protected) or to a CD. Clinical information and digital
photographs of the breast are then entered into the NIH
National Library of Medicine Interaction Tool for review
by outside experts. Each reviewer performs the evalua-
tions through the Internet using a unique username and
password. The results of their evaluations are saved in a
central database.
Selecting IBC cases at the time of diagnosis –
issues with selecting participants with one
disease from many seen at study hospitals
In many major hospitals in developing countries, includ-
ing our study cancer centers, clinics are busy with large
numbers of patients. This number could be in the range
of hundreds of patients/day [14–16].
Our challenge was to identify a rare cancer type (IBC)
before treatment from among many breast cancer cases
and other types of cancers. This challenge is not unique
to the study of IBC, but would be present at most hospi-
tals that do not have specific clinics for certain types of
cancers/diseases. We found it critical to understand the
patient flow at each study hospital. Thus, we sought to
determine (1) the department in which suspected breast
cancer cases were first seen; (2) whether suspected breast
cancer cases were seen in a different clinic/room in that
department than previously diagnosed cases; (3) in which
department/room breast cancer cases diagnosed elsewhere
were first seen; (4) how newly diagnosed cases were
referred for treatment; (5) the number and schedules of
physicians in the surgery and medical oncology depart-
ments; (6) the level of cooperation between the surgery
and medical oncology departments; (7) whether free-of-
charge patients, those with insurance, or those paying out
of pocket were seen in the same clinics; (8) whether the
hospital had a central review committee that evaluated all
new breast cancer cases; (9) whether logs (paper or elec-
tronic) of patients, including diagnosis, age, and resi-
dence, were kept in the surgery and medical oncology
departments; (10) whether senior physicians worked on a
full-time basis or divided their time between their govern-
ment or University hospital work and private practice;
(11) whether the same residents staffed the clinics every
day; (12) whether treatment was done on an inpatient/
outpatient basis; and (13) the length of time between
diagnosis and the start of treatment.
We found this evaluation absolutely necessary and
adapted our methods for identifying IBC cases to the
existing procedures at each study hospital. For instance,
at study hospitals that had a central review committee,
we identified a study collaborator who attended the meet-
ings to identify IBC cases. For study hospitals that did
not have a central review committee, we followed two
procedures: (1) we identified study collaborators who
were available in the clinics for enrollment of IBC cases
and (2) we asked study collaborators to notify clinic phy-
sicians who were not collaborators to refer IBC cases to
study collaborators. We also sought to have multiple
points of referral of IBC cases to study collaborators (e.g.,
from both the Surgery Department and the Medical
Oncology Department).
We found it particularly helpful to include junior phy-
sicians in the study, particularly at institutions that had
little rotation among the junior physicians. Linking the
study objectives to the physicians’ theses and dissertation
topics and providing educational opportunities for them
such as attending scientific conferences in North Africa or
the United States motivated them to continue their con-
tributions to the study.
We found the following issues particularly challenging
with regard to enrollment of all eligible cases: (1) ade-
quate backup duration absences of study collaborators
due to vacations, meetings, illness, or periods of study for
examinations; (2) short rotations in the medical oncology
departments for junior physicians at certain study sites;
(3) the heavy schedule of senior study collaborators; and
(4) changing hospital procedures that would interfere
with study procedures for accrual. Therefore, we highly
recommend that any study have procedures for review of
medical records to ascertain the completeness of case
accrual.
Selection of non-IBC cases – methods for
sampling comparison cases
In some types of studies, one may want to sample a cer-
tain type of cancer rather than recruit every case. This
was the case for the non-IBC comparison group in our
IBC study. With regard to comparison non-IBC breast
cancers, the challenge was to select a sample from large
pools of cases. Our methods for selecting non-IBC cases
were also based on the careful evaluation of hospital pro-
cedures that we described above and varied depending on
the hospital. We used logs kept by the surgery and medi-
cal oncology departments when available to identify non-
IBC cases matching the IBC case within 5-year age groups
and broad geographic area of residence. In other hospi-
tals, we selected non-IBC cases from cases reviewed at
weekly committee meetings. Finally, at some study sites,
we randomly selected clinics from which to find matching
non-IBC cases. To do this, we assigned a number to each
clinic from which non-IBC cases could be selected and
340 © 2012 The Authors. Published by Blackwell Publishing Ltd.
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then used a simple SAS random number algorithm to
randomize the assigned clinic numbers to determine from
which clinic each non-IBC case was to be selected. If
more breast cancer cases were seen at one clinic com-
pared with another (e.g., if 80% of patients at a hospital
were seen in a “free” clinic and 20% of patients in an
“insurance/private” clinic), we assigned numbers to the
clinics in proportion to the number of cases they saw.
Depending on the level of cooperation between the sur-
gery and medical oncology departments, we selected non-
IBC cases before or after mastectomy.
The determination of the clinic from which each non-
IBC case was to be selected was done at the NCI-USA and
was communicated to the study collaborators as described
in the section “Logistics of study implementation.” We
ascertained from questions on our forms whether collabo-
rators were adhering to the randomization scheme.
Controls
We did not select population-based controls because we
were not assured that our cases were population based.
Furthermore, it would not have been feasible to select
population-based controls because such things as tele-
phone use and driver’s license registration are very
incomplete in the areas where our study is being con-
ducted. We also faced additional challenges in recruiting
controls. We could not recruit noncancer controls from
our study patient populations because most sites were
cancer centers. Noncancer hospital-based controls were
not feasible because we would have had to enlist the
cooperation of nearby general hospitals, thereby greatly
increasing the complexity of the study. Therefore, we
chose to select controls from those visiting certain types
of other cancer patients at our study hospitals, as has
been done in other studies [17–21]. To do this, we evalu-
ated at each study hospital (1) the number of inpatient
surgical and medical oncology wards, the number of
rooms in each ward, and the number of beds in each
room; (2) whether there were separate inpatient wards for
free-of-charge patients, those with insurance, or those
paying out of pocket; (3) whether there were inpatient
wards for patients coming from a distance; (4) visiting
days and hours; (5) whether there was a charge for visit-
ing; (6) methods for ascertaining the diagnosis for the
patients in each hospital bed; and (7) availability of study
staff to complete study procedures, including interviews,
during visiting hours. Based on this information, we
developed randomized procedures to choose the wards
from which to choose noncancer visitors of other cancer
cases. We used simple randomization schemes similar to
those we used for randomly selecting clinics for identify-
ing non-IBC cases. For instance, we assigned a number to
each ward from which visitors could be selected, then
used a simple SAS random number algorithm to random-
ize the assigned ward numbers to determine from which
ward each visitor was to be selected. We attempted to
make the visitor selection reflective of the patient popula-
tion by assigning multiple numbers to types of wards with
the largest patient population (e.g., if 80% of the patient
population was in “free” wards vs. 20% in “insurance/pri-
vate” wards, we assigned 80% of the random numbers to
the “free” wards and “20% to the “insurance/private”
wards). We designed our forms to ascertain whether the
randomization schemes were being followed. The deter-
mination of the ward from which each visitor was to be
selected was done at the NCI-USA and was communi-
cated to the study collaborators as described in the sec-
tion “Logistics of study implementation.”
Particular challenges with selection of controls included
(1) finding interviewers who were available during visiting
hours; (2) finding visitors meeting the matching criteria
for age and geographic residence; and (3) convincing the
study collaborators that recruiting controls was as impor-
tant as recruiting cases. Many clinicians have experience
with research that involves cases but no controls.
Logistics of study implementation
As noted previously, our study was low-budget and there-
fore, necessarily low-technology. Therefore, we used sim-
ple methods for study implementation. As noted
previously, the hospitals that participated in this study
saw a high volume of patients and were crowded and
busy. In this setting, management of study documents to
ensure completion of all required steps and to minimize
loss of study materials is very important. Thus, we
included all study materials for each study subject in an
inexpensive 1-inch three-ring plastic binder with study
documents in the order in which they were to be admin-
istered and dividers indicating who was to administer the
study documents. Instructions were placed at the begin-
ning of the binder. Forms included selection forms for
visitor controls, eligibility forms for IBC and non-IBC
cases, consent forms, the questionnaire, clinical examina-
tion forms, medical record review forms, pathology report
forms, instructions for saliva collection and anthropo-
metric measurements, and taking digital photographs. We
designed selection and eligibility forms to record non-
response, which is crucial to report for publication and
for understanding whether the subjects enrolled in the
study reflect the populations of interest. For instance, if
visitors were eligible but refused, this was recorded on the
visitor selection form. If IBC or non-IBC cases were eligi-
ble, but refused, this was recorded on the eligibility forms.
A plastic pencil case was placed at the beginning of the
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binder to hold the vials for saliva collection. Labels identi-
fying the study hospital, the type of study subject, the
study ID number, the age category, and broad geographic
area of residence for matching were placed on the cover
of the binders. For non-IBC cases and visitors, the clinic
or ward from which the study subject was to be selected
was also identified on a label placed on the cover of the
binder. Each subject type (IBC, non-IBC, visitor control)
had a different color binder. These binders were assem-
bled in the United States and shipped to study hospitals.
To facilitate the shipping of the binders, we completed an
NIH 1884-1 Commercial Invoice form that allowed deliv-
ery of the binders directly to the study hospitals. Without
this form, study collaborators had to pick up the binders
at the customs office. On occasion, we have had some
difficulty getting the saliva vials through customs in the
collaborating countries. In fact, at some sites it became
necessary to hand carry saliva vials during travel by U.S.
study collaborators to avoid problems with customs.
With regard to response rates, particular challenges
included persuading clinicians that it was important to
record nonresponse. It was also challenging to design
forms that recorded nonresponse of eligible subjects but
not nonresponse of ineligible study subjects.
Data keying was done at the study sites using Viking
Data Keying Software, a straightforward, well-documented
commercial system. The double-keyed data files are
uploaded to the study portal at the study sites and are
then downloaded from the portal and merged into SAS
datasets in the United States.
In addition to being used for posting keyed data files
and photographs, the study portal is also used to post all
the documents for the study and to provide links for
Institutional Review Board (IRB) and Federal-Wide
Assurance (FWA) Registration.
Questionnaires and Interviewing
The design of clinical forms and medical review forms
was developed in collaboration with the local clinicians in
each site. The clinicians’ input was extremely helpful in
developing user-friendly forms that capture all the needed
clinical information.
Design of the epidemiologic questionnaire was chal-
lenging because the study is in three countries, with
patients coming from both rural and urban areas. To
accurately capture information related to socioeconomic
status, education, occupation, contraception, childbearing,
and breastfeeding in the different study populations, we
talked extensively to study collaborators and used data
from national surveys and other publications to help in
determining questionnaire content. Important resources
in questionnaire development included the following:
(1) Egypt demographic and health survey 2005 [22];
(2) Socioeconomic differences in Health, Nutrition, and
Population – Egypt 2000 and Morocco (2003–2004) com-
piled by the Health, Nutrition, and Population (HNP)
Family of the World Bank’s Human Development Net-
work [23]; (3) Measuring women’s work in developing
countries [24]; (4) Economic and social conditions in
North Africa – Part III – the economic participation of
women in North Africa [25]; (5) women’s time use survey
in Morocco [26]. We also found information on the distri-
bution of smoking, obesity, female literacy, contraceptive
use, and consanguinity from other sources [27–34]. We
also researched the leading crops grown in each country
and the types of pesticides most commonly used.
Cultural sensitivity in developing the questionnaires,
setting up the order of questions, and developing ques-
tions for sensitive issues was very important. For example,
we learned that we should not start the questionnaire by
asking about some demographic information of patients.
We were told that starting the epidemiologic question-
naire with the demographic section will sound like a
“police interrogation” of subjects. In our study, we
included address, contact information, or relatives to be
contacted in the future, if needed, age, place of birth, and
marital history in the beginning but household conditions
and appliances farther back in the questionnaire. It
should be noted that the order of questions is culture
specific, and it should be considered based on the local
culture, preference, and settings in each country or
region. As an example of a culturally sensitive topic, we
were interested in including questions about subjects’
exposure to mice in the household environment. We were
advised by the local clinicians to tailor the sets of ques-
tions on this topic in an indirect way because it would be
considered insulting to ask about mice in the household.
We were advised to begin by first asking about subjects’
knowledge of mice control campaigns in their neighbor-
hood, followed by asking about their knowledge of mice
in neighbors’ homes, and finally asking about their use of
rodenticides for killing mice in their homes. We also tried
to be culturally sensitive to perceptions about cancer. For
instance, local clinicians told us that some women refer
to breast cancer as the “bad” disease of the breast, call
malignant tumors “female” and benign tumors “male,”
and refer to cancer hospitals as “bad” hospitals. We pilot
tested the questionnaire with employees of the study
hospitals from a variety of backgrounds.
Study subjects were administered the questionnaires by
interviewers. Although patients and physicians in the
Egypt, Tunisia, and Morocco all speak Arabic, different
dialects of Arabic are spoken in each country [2]. Some
Tunisians and Moroccans also speak French, but others
do not. Thus, we translated the questionnaire into the
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spoken Arabic dialects for each country and also into
French.
The final version of the questionnaire included the fol-
lowing sections in this order: contact information; age;
religion; ethnic background; childbirth history; educa-
tional background of study subject; marital status; hus-
band’s educational and occupational background;
menstrual history; contraceptive history, infertility, and
menopausal hormonal use; breastfeeding history; medical
history; family history of breast cancer; agricultural his-
tory; other occupational history; anthropometry; exposure
to tobacco smoke; residential history and household
appliances as surrogates for income; access to health care;
level of cooperation in the interview; and current body
measurements. The order of the above-listed sections of
the questionnaire yielded the best flow of delivering the
questions and cooperation of study subjects as shown in
the pilot testing of questionnaires.
For some study subjects, the questionnaire, which on
average took 45–60 min, seemed long and interviewers
had to give them breaks in order to complete the entire
questionnaire. Some patients have difficulty in recalling
age at childbirth, age at starting and stopping contra-
ceptive use, age of starting different agricultural occupa-
tions, and exact weight at different ages. To help recall of
ages at childbirth, we also obtained information on the
current ages of the children, so that we could subtract the
current age of the children from the study subject’s cur-
rent age to obtain the study subject’s age at the birth of
each of her children. The interviewers reminded the sub-
jects of their childbirth history to help them recall their
periods of contraceptive use. They used age of marriage
and other major life events to help them recall ages of
different agricultural and other occupations. With regard
to weight, the questionnaire also included a diagram of
body types at different ages, which the study subjects were
able to complete. We also measured current body weight,
height, and hip, waist, and chest circumference. Gender
of the interviewer was also important. In one study hospi-
tal, the only interviewer available was male, and he was
uncomfortable asking about bra size and taking chest and
hip measurements. To compensate for this, the study cli-
nician asked these questions and took the measurements.
Medical examination and review forms were in English
in Egypt because English is the medical language of medi-
cal education. French was the language of the same forms
in Tunisia and Morocco. Translation of questionnaires
into spoken Arabic dialects was challenging because most
professional translators are comfortable with translation
into standard Arabic, not into spoken colloquial Arabic.
This resulted in considerable review and revision and
back-translation of the translated documents. A possible
alternative would have been to have the questionnaires in
standard Arabic and to have the interviewers translate
orally into spoken Arabic dialects, but this would have
resulted in less standardization of the spoken dialects.
Consenting is also a subject that should be considered
with care in developing countries. The reasons include
the large percent of illiterate patients who cannot read
and sign the consent form. In addition, because of the
need for free medical care, some patients may have the
impression that they might not receive medical care if
they do not participate in research studies. We had to be
very explicit in the wording of the consent forms to
avoid this possible impression. We had to have a witness
sign the consent form after its verbal reading to each
study participant who could not read or write. Witnesses
were typically family members and that facilitated the
consenting process and the high response rate of partici-
pation in the study. On some occasions, the husbands of
potential study subjects refused to allow their wives to
participate in the study even though the wives wanted to
do so. In other middle- and low-income countries, the
effect of the relationship with the witnesses needs to be
investigated on consenting and study participation.
Patients were asked to consent on each section of the
study (e.g., interviewing, providing saliva samples, agree-
ing to use the tumor tissues in case of IBC and non-IBC,
and taking photographs of their breast without showing
their face).
Biologic Specimens
We encountered the following issues in obtaining paraffin-
embedded tumor tissue specimens: (1) ensuring that the
method of formalin fixation is adequate to obtain viable
DNA; (2) obtaining sufficient tumor tissue using the stan-
dard diagnostic techniques in the study hospitals;
(3) obtaining tumor tissue for cases diagnosed outside
the study hospitals; and (4) reluctance of collaborators to
share their paraffin blocks for research outside the home
country.
We addressed the appropriate method of fixation by
providing the standard protocol for preparing paraffin
blocks that we used at the University of Texas M. D.
Anderson Cancer center in the late 1990s. There were few
differences between the M. D. Anderson protocol and the
local protocols except that the latter used concentrated
formalin for preserving the tissues after resection and
possibly long duration (1–2 days) between resection and
processing. Our M. D. Anderson protocol used 10% for-
malin and a processing of specimens within 3–4 h. We
were able to persuade the local institutions to follow the
U.S. protocol because all it required was dilution of the
formalin with water without any expenditure of money
or other resources. With the U.S. protocol, we were able
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to obtain viable tissues that we used in our subsequent
studies [6, 12, 35–37].
With regard to obtaining sufficient tumor tissue, it is
critical to determine what diagnostic techniques are stan-
dard in study hospitals. For instance, diagnosis of breast
cancer, including IBC, is frequently done by fine needle
aspiration, but this method does not yield sufficient tissue
for research purposes. A true cut biopsy is more likely to
yield sufficient tumor tissue, although yield might not
always be enough and is less than is obtained from mas-
tectomy specimens. Because a true cut biopsy also has
advantages in terms of diagnosis, our collaborating clini-
cians agreed to do true cut biopsies instead of fine needle
aspiration biopsies to accommodate the research study.
With regard to obtaining tumor tissue for cases diag-
nosed outside the study hospitals, we note that it is often
customary for patients to bring their slides from the diag-
nosing hospital or pathology laboratory to the study hos-
pital. Personal communication of the study clinicians and
pathologists with the hospital or laboratory where the
biopsy was done is extremely important for having a
complete set of tissues. Many tissues that were diagnosed
outside our collaborating cancer centers were processed at
private laboratories of the institutions’ pathologists and
were prepared according to our study protocols.
It is important to do periodic checks of the quality of
DNA from the tissues obtained from the collaborating
cancer hospital or private laboratories to ensure high
quality. Pathological diagnosis is always confirmed by our
collaborating pathologists in North Africa and the United
States. Embedding of tissues in cassettes varied between
the collaborating institutions and sometimes needed re-
embedding in the United States if tissues are directly fixed
on paraffin without cassettes. Relying on bar-coding of
specimens in developing countries should not be selected
as an option because of lack of scanners and computers
that would download and read scanned numbers. Instead,
it would be useful to scan and print IDs before shipping
forms and labeling tissues and slides after they are
received in the United States.
Regarding the reluctance of collaborators to share their
patients’ paraffin blocks outside the country, this was
mainly due to country rules on exporting biologic speci-
mens or their interest in local technology transfer to their
country. We understood the country restrictions on
exporting tissue blocks and instead we obtained cut tissue
slides instead of paraffin blocks. When technology transfer
was the issue, we followed three approaches: (a) we devel-
oped tissue microarrays in the United States and shared
duplicates with the local collaborators; (b) we supplied
the local collaborators with reagents to perform the labo-
ratory assays locally and compared the quality with the
U.S.-generated results from the same specimens; or (c) we
provided training to the local collaborators in the United
States to return back to their home countries to perform
the laboratory assays.
Obtaining saliva samples is being accomplished using
Oragene saliva collection kits, which can be stored at
room temperature for years, require no special prepara-
tion or handling, and are easy to use by study subjects,
for the most part. The only precautions for saliva collec-
tion are the need for the subject to avoid drinking,
eating, or chewing gum for 30 min before spitting and
the possible expiration of the reagent included in the sal-
iva tubes for preservation, if the tubes are kept past their
shelf life.
Regulations regarding the import of biologic samples
into the United States can be found at the following web-
site: http://www.cdc.gov/od/eaipp/faq.htm. Etiologic Agent
Import Permits are not required for the transport into
the United States of noninfectious materials – for exam-
ple, formalin-fixed specimens, tissues, or slides, and
human or animal diagnostic specimens such as blood,
urine, and tissues in which there is no evidence or indica-
tion that such material contain an infectious agent. How-
ever, the following recommendation is taken directly
from the CDC website: CDC advises that importers of
materials that do not require a CDC import permit
include a signed statement, on their official letterhead,
from the person responsible for the shipment of this
material with the following information:
(a) a description of the material;
(b) a statement that this material meets one of the above
criteria (e.g., human urine diagnostic specimens in
which there is no evidence that such material contain
an etiologic agent); and
(c) verification that the material has been packaged,
labeled, and transported in accordance with all appli-
cable regulations.
Training, Quality Control, and Data
Management
We tried group training of interviewers and study coordi-
nators at one of the collaborating sites in North Africa,
but the efficiency of this training was lower than our site
visits to individual hospitals and sites. For instance, visa
issues and agreeing on one place and time period where
the collaborators leave their routine hospital work were
limiting factors for the effectiveness of the group training.
Students from the University of Michigan School of Pub-
lic Health and Cancer Center also help in monitoring the
study. They conduct summer research projects funded by
the NCI through an R25 educational grant and the Univer-
sity of Michigan research and training grants. The students
travel to monitor the study, train local collaborators, and
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streamline unresolved issues. Involving students was very
helpful in facilitating IRB, questionnaire design, testing the
questionnaire, and monitoring the study and their research
resulted in several publications [2, 36–44]. For instance,
one student is reviewing medical records during the period
of the study to assess the adequacy of our case accrual
methods and reliability of medical records in identifying
any missed cases during our study recruitment.
Involvement of students was a useful research experi-
ence for them in international epidemiology and facili-
tated the field study.
In addition, the University of Michigan in collabora-
tion with the Office of International Affairs of NCI has
sponsored the University of Michigan Graduate Summer
Courses in cancer epidemiology and translation of epide-
miology to cancer prevention and control. Several of our
collaborating clinicians from North Africa have partici-
pated in these courses and the exchange of knowledge
and experience improved their engagement in the study
and understanding of epidemiologic methods and appli-
cations to cancer prevention.
We used simple EXCEL files for study management in
the United States and at some study sites. Other sites
used paper study management systems because computer
access was difficult. Low-technology study management
procedures were more successful because of lack of high-
efficiency computer systems, available high-speed Internet,
and absence of other advanced technological procedures
such as wireless Internet connection, remote access of
computers, and institutional servers with automatic back-
ups that are increasingly becoming routine in U.S.-based
research studies. In fact, home availability of the Internet
in Egypt and Tunisia ranges between 25% and 40% [45].
While investigators have high-speed Internet for their per-
sonal use at home, government hospitals in North Africa
still have limited Internet capabilities. The study has a
portal for uploading breast photos and keyed data, but
this was sometimes difficult for collaborators to access
due to poor Internet connections. It is important to note
that with expanding Internet technology in developing
countries, there are new tools for better Internet connec-
tion even without relying on the infrastructure of hospi-
tals. Wireless Internet cards, modems, and high-speed
Internet from cell phone connections are becoming avail-
able in many developing countries.
Regulatory Requirements
For an international multicenter study like ours, with
inclusion of a U.S. Federal Government funding compo-
nent, the regulatory requirements that had to be met were
many. These included approvals from IRB at sites in the
United States and in the collaborating countries, FWA
registration for all collaborating institutions, and payment
(Central Contractual Registration [CCR] and the Online
Representations and Certifications Applications [ORCA]).
While these approvals and certifications are routine pro-
cedures for researchers in the United States, they were a
challenging experience for our international collaborators.
Issues were (1) lapsed IRB and FWA registrations at some
study sites; (2) disbanded IRB committees that had to be
reconstituted according to U.S. regulations; (3) compli-
cated registration instructions that were not in the native
language of the study collaborators; (4) intimidating legal
language; (5) difficulty in remembering passwords and
access codes to the electronic websites; (6) poor computer
access; (7) signatory officials who were not part of the
research team; and (8) registrations lapsing during the
course of the study because not all collaborators routinely
check e-mails, thus missing notifications that registrations
needed to be renewed. We had to walk the collaborators
through the certification process through numerous
emails and site visits. At some sites, we also found that
IRB committees did not meet until they had a sufficient
number of protocols to review. Thus, plenty of time
should be allowed to accomplish these registrations. U.S.
collaborators should make every effort to be cognizant of
registration lapse dates. Information on U.S. Government
regulations regarding IRBs and FWAs can be found at the
following address: http://www.hhs.gov. Ethical guidelines
for international studies can also be found in the book
“International Ethical Guidelines for Epidemiologic Stud-
ies” from the Council for International Organizations of
Medical Sciences (CIOMS) studies. We note that the
Health Insurance Portability and Accountability Act of
1996 (HIPAA) does not pertain to institutions in low-
and middle-income countries.
The system of invoicing to the NCI and reimbursement
after provision of the service of recruitment was a new
concept for our international collaborators. It is impor-
tant to note that our payment system was based on
recruitment of triplet sets of IBC, non-IBC, and control
subjects. This payment system for studies in developing
countries is significantly more efficient than payment on
percent salary effort or monthly basis as is the case in the
United States. Because of low salary levels in developing
countries, the percent effort compensation does not work
there.
Other Logistical Considerations
In the current era of global and international health,
political circumstances are an integral part of the dynam-
ics of joint research and international collaborations. The
changing politics in the Middle East starting from the
Iraq war in 2003, which delayed the start of the study,
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and the revolutions in Egypt and Tunisia in 2011, which
slowed the flow of patients to study hospitals due to secu-
rity concerns, have had their impact on the pace of the
research study. In fact, we had to extend our contracts to
the study sites to account for accrual over a longer period
of time.
Other logistical points to consider include understand-
ing the hierarchy and internal politics of the collaborating
institutions, the importance of inclusion of senior, mid-
career, and junior collaborators, understanding the system
of retirement for senior collaborators, and finding oppor-
tunities for motivating clinicians to collaborate on an epi-
demiologic study by including aspects related to clinical
research, financial incentives, and other opportunities for
professional growth, such as authorship on manuscripts
or training in epidemiology. For instance, some of our
clinician collaborators were interested in measuring breast
size from mammograms, so we incorporated questions
about this in our medical record review form. Other cli-
nician collaborators are participating in a clinical trial of
IBC during the same period of time as the epidemiologic
study, which increased interest and motivation. We fur-
ther funded training of several collaborators at short epi-
demiology courses conducted in the Mideast by the first
author of this article.
Important Efforts Not Successfully
Undertaken
We attempted to measure breast size in two ways: by
obtaining information on bra size on the questionnaire
and by recording certain measurements from the mam-
mograms (vertical, horizontal, and diagonal dimensions
of the breast). However, our efforts were not entirely suc-
cessful because women living in rural areas frequently do
not wear bras. Moreover, the physicians were not used to
making the measurements on the mammograms so these
measurements were rarely made. Successful implementa-
tion of the mammographic approach would require more
extensive training than we did. Breast immersion and
measuring the volume of water replaced were impractical
in a routine hospital setting. Developing new feasible and
practical methods for estimating breast size would be
important for epidemiologic studies of breast cancer con-
sidering the wide range of variation in breast size between
populations.
Our study would have benefited from more frequent
and longer site visits by U.S. principal investigators. In
general, we had funding to do two site visits per year,
with 1–3 days at each study site. It would have been help-
ful to have four site visits per year, with a minimum of
2 days at each site. Students were funded for a period of
3–4 months, the limit allowed by the training grant and
their class schedules. Additional funding for more
extended stays and more flexible and tailored curriculum
of students would have enabled them to stay longer at
each site.
Regular use of advanced tools of electronic communi-
cation with the collaborators in North Africa would be
helpful. Currently, there are software programs such as
Adobe Connect that enable verbal and visual communica-
tion and sharing and editing of documents between
collaborators at different international locations. Use of
these techniques would enhance effective communication
at limited cost.
Diagnostic criteria for cancers other than IBC, such as
hematologic malignancies, may differ among countries.
Therefore, teaching sessions by expert pathologists should
be included in the studies of such cancers in order to
minimize diagnostic differences among study sites. Studies
of cancers that require diagnostic imaging (e.g., liver and
pancreatic cancers) might require upgrading the infra-
structure of the recruiting hospital and physician training
to capture the cases.
We have summarized our recommendations for the
planning and conduct of epidemiologic studies in low-
and middle-income countries in a checklist (Table 1).
Table 1. Checklist of critical elements for assessing feasibility of an
epidemiologic case–control study at a site in low- and middle-income
countries.
(1) Study site(s) has willing collaborators and qualified staff to
conduct the study.
(2) A sufficient number of cases can be accrued.
(3) Cases can be identified at or near the time of diagnosis.
(4) Medical records with patient and clinical information are
available at study site.
(5) Biologic specimens that are sufficient and suitable for research
purposes can be collected.
(6) Study hospital is willing to release biologic specimens for research.
(7) A suitable control group can be found (either at study hospital,
affiliated or neighboring hospital, from the neighborhood or
population based).
(8) Protection of human subjects is adequate.
Checklist for critical elements for study implementation
(1) Detailed scientific protocol.
(2) Adequate funding.
(3) Development of study forms and documents.
(4) Pretesting of forms and documents, including questionnaire.
(5) Training of study personnel.
(6) Quality control procedures.
(7) Adequate provisions for study management and data keying.
(8) Permits for obtaining and shipping biologic specimens.
(9) Obtain clearances related to protection of human subjects.
Checklist for desirable elements
(1) Develop sustainable infrastructure for future studies.
(2) Train personnel for future studies.
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Discussion
Our experience in conducting this epidemiologic study in
North Africa highlights the importance of the some gen-
eral points for those interested in future epidemiologic
case–control studies in North Africa and other middle- or
low-income developing countries.
(1) It is very important to understand the healthcare sys-
tem of the country and the cultural and behavioral
factors related to seeking medical care. This includes
understanding the referral patterns of cases to study
hospitals. This information is crucial for efficient
recruitment, selection of an appropriate control
group, and generalization of the results. For instance,
if many cases of the disease of interest never seek
health care, it is not recommended that population-
based controls be used.
(2) In selecting a control group, it is also very important
to understand the culture of the country. For
instance, if telephone use and driver’s license registra-
tion are very incomplete in the areas where the study
is going to be conducted, certain methods for select-
ing controls, such as random digit dialing, are not
recommended.
(3) Defining the precise clinical and/or pathological nat-
ure of the disease to be studied is essential and may
vary by the cancer site/type to be studied. For exam-
ple, precise clinical diagnosis is the most important
diagnostic element for IBC. On the other hand, pre-
cise pathological and/or immunological diagnosis is
the most important element for inclusion of lym-
phoma cases in epidemiologic studies.
(4) Epidemiologic studies should consider the inclusion
of clinical components and/or coordinate with clini-
cal trials of the same disease that might be underway
in study hospitals. This point is especially important
because of the limited number of trained cancer epi-
demiologists in developing countries and the leader-
ship of research studies by clinicians. In the
meantime, training and creation of a new cadre of
trained cancer epidemiologists is also important.
(5) Readiness for unexpected changes in the pace of the
study due to political, personnel, or hospital setting
changes is crucial. Alternative plans should be consid-
ered and be available for continuation of the study
under new circumstances.
(6) It is important to explore all avenues for funding and
training of junior clinicians, study managers, and
interviewers. Sending collaborators to short courses
in cancer epidemiology, offering training options in
the United States, and inclusion of students from the
United States into the study are very helpful. Cou-
pling of local and U.S. students can also add many
benefits to the progress and quality control of the
study.
(7) It is also important to appreciate technical difficulties,
busy clinics, and overloaded local systems for patient
care in developing countries. It is important to con-
sider reliance on low-technology methods for data
management, quality checking, and monitoring of the
study rather than high-technology sophisticated soft-
ware system that require high-speed Internet and
other technology that might not be regularly available
in hospital settings.
(8) It is important to know that there are likely unwrit-
ten cultural codes in middle- and low-income coun-
tries and their hospitals. For instance, internal
conflicts between departments and fear of displeasing
mentors or powerful institutional leaders may consti-
tute unwritten codes that hinder the progress of the
study. It should be noted that understanding such
conflicts may need time and close engagement with
the collaborators. In some middle- and low-income
countries, the primary income of cancer center fac-
ulty will be earned in their private practice. Some-
times, their service at the university will be unpaid.
Consequently, university department chairs, deans,
and administrators might have little power to influ-
ence their faculty members, and this can come as a
surprise to researchers from high-income countries.
Therefore, it is important to consider whether a par-
ticular collaborator should be compensated with
financial incentives separately from the grant budget
that is allocated for the cancer center or through
other means. Private discussions must resolve these
matters. Other unwritten codes include the difficulty
and misunderstanding of spoken English. Further-
more, “yes” does not always means “yes” and “no”
does not always mean “no.” There are also many cul-
tural barriers that may prevent collaborators from
expressing their disagreement. For example, research-
ers and clinicians may feel embarrassed to inform
their collaborators from high-income countries of
their disagreement about a study procedure or feasi-
bility of success of a study procedure. The result will
be a false impression of agreement while failure of
achievement will be the outcome. On the other hand,
researchers and clinicians may show rejection of cer-
tain study procedures or techniques because of their
lack of knowledge of this procedure or its implemen-
tation. Because they may feel that they may be dis-
pleasing the collaborators from high-income
countries if they admit so, they may reject the proce-
dure rather than learning about it.
We expect that there will be many overlapping points
between our experience on the epidemiology of IBC in
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North Africa and other research studies on breast or
other cancers in other middle- or low-income developing
countries. Possible variations between our experience and
future research studies include the level of development
of the country, study design, cancer site, cultural and
behavioral factors of populations, access to medical care,
referral systems of patients, and the medical education of
the country. While we attempted to maximize the success
of our study using the methods described in this article,
other study- and region-specific measures may be tailored
according to the aims and local circumstances of the
study setting to enhance opportunities of success.
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